Romosozumab

Bone remodeling

Increase bone formation and reduce resorption

Reading this compound Reference only

Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.

Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.

Mechanism & Use

Compound type: Monoclonal antibody
Primary mechanism: Sclerostin inhibition
Primary market use: Osteoporosis

Pharmacology

Molecular weight (Da): ~149,000
Oral bioavailability: N/A
Half-life: ~12.8 d
Route tags: Route-dependent / verify
Evidence level: Approved
Clinical status: Approved
Value-for-money score: 7 / 10

Reported protocol signal

No popular protocol verified yet; keep as reference compound until protocol signal is added.

For orientation only. See disclaimer — always consult a licensed clinician before use.

Notes

Structural bone-density change; effects require management

Sources

https://www.fda.gov/drugs